Wednesday, July 8, 2026

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda is a pharma organization headquartered in Cambridge, USA. Primary therapeutic focus areas include Diabetes Mellitus, Hemophilia A, Crohn's Disease, Hypertension, Type 2 Diabetes Mellitus. NovaPharmaNews links 1179

Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Clinical program

Tak-228 & Tak-117

Phase 2 · small molecule · Triple Negative Breast Cancer

Tak-228 & Tak-117 for Triple Negative Breast Cancer is a Phase 2 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).

← All Takeda projects Phase 2 small molecule completed

Internal code 017- 113

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Takeda
Phase
Phase 2
Modality
small_molecule
Indication
Triple Negative Breast Cancer
Status
completed
Trials
1

Clinical trials